Trial Profile

A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; WXFL 10030390 (Primary)
Indications Carcinoma; Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Jiatan Pharmatech

Most Recent Events

30 Apr 2025 Results (As of January 14, 2025, n=49) assessing safety and efficacy of WX390 combined with toripalimab in patients with advanced cervical cancer presented at the 116th Annual Meeting of the American Association for Cancer Research
25 Nov 2024 Planned End Date changed from 1 Mar 2025 to 9 Nov 2025.
25 Nov 2024 Planned primary completion date changed from 1 Mar 2025 to 9 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com